Bookmark and Share
nifursol (CID 9570327) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(35)
 
 
Inactive(96)
 
 
Inconclusive(59)
 
 
Unspecified(133)
 
 
Top Targets:
7TM GPCR Srsx(17)
 
 
 
7TM GPCR Srx(17)
 
 
p450(10)
 
 
 
 
 
NR LBD ER(9)
 
 
 
 
NR LBD PPAR(8)
 
 
 
BioAssay Types:
Confirmatory(98)
 
 
 
 
Literature(66)
 
 
 
 
 
Summary(24)
 
 
 
 
Screening(2)
 
 
BioActivity Types:
IC50(116)
 
 
 
Potency(115)
 
 
 
 
EC50(2)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 260    Data Row: 323   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID170466422]
Ratio Potency (uM) 2.9847qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary [AID743219, Type: summary]nuclear factor erythroid 2-related factor 2 isoform 1 [Homo sapiens] [gi:20149576]
View
2
[SID103646320]
IC50 5DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625247, Type: other]Cytochrome P450 2C19 [gi:60416369]
View
3
[SID103646320]
IC50 7DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625248, Type: other]Cytochrome P450 2C9 [gi:6686268]
View
4
[SID103646320]
EC50 15Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay [AID547622, Type: Literature]
View
5
[SID144205448]
Potency-Replicate_1 26.6032qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability [AID651633, Type: confirmatory]
View
6
[SID144205448]
Potency-Replicate_1 29.8493qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen [AID743086, Type: confirmatory]
View
7
[SID29216239]
Potency 36.1254Biochemical firefly luciferase enzyme assay for NPC [AID624030, Type: confirmatory]Luciferase [Photinus pyralis] [gi:160794]
View
8
[SID144205448]
AhR Potency (uM) qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary [AID743122, Type: summary]aryl hydrocarbon receptor [Homo sapiens] [gi:51095037]
View
9
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_52, Type: Literature]
View
10
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_48, Type: Literature]
View
11
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_49, Type: Literature]
View
12
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_42, Type: Literature]
View
13
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_43, Type: Literature]
View
14
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_44, Type: Literature]
View
15
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_39, Type: Literature]
View
16
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_40, Type: Literature]
View
17
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_46, Type: Literature]
View
18
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_54, Type: Literature]
View
19
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_1, Type: Literature]
View
20
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_4, Type: Literature]
View
21
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_6, Type: Literature]
View
22
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_7, Type: Literature]
View
23
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_8, Type: Literature]
View
24
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_10, Type: Literature]
View
25
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_11, Type: Literature]
View
26
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_13, Type: Literature]
View
27
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_15, Type: Literature]
View
28
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_16, Type: Literature]
View
29
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_18, Type: Literature]
View
30
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_21, Type: Literature]
View
31
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_25, Type: Literature]
View
32
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_26, Type: Literature]
View
33
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_29, Type: Literature]
View
34
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_35, Type: Literature]
View
35
[SID29216239]
qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749_37, Type: Literature]
View
36
[SID103646320]
EC50 50Cytotoxicity against BESM cells after 88 hrs by HTS assay [AID547621, Type: Literature]
View
37
[SID103646320]
IC50 DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) [AID625223, Type: other]Sigma non-opioid intracellular receptor 1 [gi:74752153]
View
38
[SID103646320]
IC50 DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) [AID625172, Type: other]Progesterone receptor [gi:75071465]
View
39
[SID103646320]
IC50 DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625249, Type: other]Cytochrome P450 2D6 [gi:84028191]
View
40
[SID103646320]
DRUGMATRIX: Chemokine CXCR1 (IL-8A) [AID625240, Type: other]C-X-C chemokine receptor type 1 [gi:108936015]
View
41
[SID103646320]
IC50 DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) [AID625251, Type: other]Cytochrome P450 3A4 [gi:116241312]
View
42
[SID103646320]
IC50 DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625162, Type: other]Kappa-type opioid receptor [gi:116242691]
View
43
[SID103646320]
IC50 DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) [AID625148, Type: other]Melanocortin receptor 4 [gi:60392672]
View
44
[SID103646320]
IC50 DRUGMATRIX: Vascular Endothelinal Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) [AID625231, Type: other]Vascular endothelial growth factor receptor 1 [gi:143811474]
View
45
[SID103646320]
IC50 DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) [AID625227, Type: other]Substance-K receptor [gi:229462950]
View
46
[SID103646320]
IC50 DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) [AID625144, Type: other]Leukotriene C4 synthase [gi:239977155]
View
47
[SID103646320]
IC50 DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) [AID625229, Type: other]Thromboxane-A synthase [gi:254763392]
View
48
[SID103646320]
IC50 DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) [AID625178, Type: other]Matrix metalloproteinase-9 [gi:269849668]
View
49
[SID103646320]
IC50 DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) [AID625167, Type: other]cGMP-specific 3',5'-cyclic phosphodiesterase [gi:317373261]
View
50
[SID103646320]
IC50 DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) [AID625243, Type: other]Prostaglandin G/H synthase 1 [gi:317373262]
View